CA-JSR-LIFE-SCIENCES
2.5.2022 14:27:09 CEST | Business Wire | Press release
JSR Life Sciences, LLC (JSR) today announced that Mark W. Womack will serve as the Chief Executive Officer of two of its affiliate companies: KBI Biopharma , a leading global CDMO specializing in drug development and biologics manufacturing, and Selexis SA , an industry-leading cell line development provider. Womack will be responsible for the strategic vision, continued growth, and organizational culture of both organizations, which currently includes eight facilities in Europe and the U.S. Womack’s appointment is effective May 2, 2022. He will report to JSR Life Sciences President Tim Lowery.
“Mark’s impressive track record includes extensive CDMO and biologics experience, as well as the ability to deliver overall growth, revenue generation, and organizational alignment,” said Tim Lowery, President, JSR Life Sciences . “His innate commitment to quality and innovation is a natural fit for the JSR family and a significant win for Selexis and KBI partners and employees. I look forward to working with Mark and his teams as we continue to provide best-in-class capabilities for outsourced drug development and manufacturing services.”
Womack brings a consistent track record of successful leadership and life sciences experience to KBI and Selexis. He most recently served as the CEO and Managing Director of Stelis Biopharma, where he oversaw the development and implementation of the infrastructure for a pure-play CDMO, including an end-to-end biologics offering, across multiple facilities. In 2021, he led the company’s efforts to build and qualify a state-of-the-art vaccine facility capable of clinical and commercial-scale manufacturing in record time.
Prior to Stelis, Womack served as the Chief Business Officer at AGC Biologics, in which his extensive experience driving organizational performance improvements led to a nearly 300% increase in new sales in just two years. His career began with more than ten years of distinguished service in the U.S. Navy, where he was recognized with many of their highest honors for exceptional leadership.
“KBI and Selexis are helping create a world where everyone has access to vital treatments that improve or extend their lives,” said Womack. “I’m honored to join JSR and these two great organizations in their mission to help our clients solve their greatest scientific challenges – in turn, providing life-saving therapeutics to patients across the globe. I look forward to supporting the KBI and Selexis teams’ continued growth trajectory and building on their long commitment to quality and innovation.”
Womack joins KBI and Selexis amid a period of profound expansion for both companies. In April, KBI cut the ribbon on its new state-of-the-art $150 million, 150,000 square-foot commercial manufacturing facility in Research Triangle Park (RTP), North Carolina. This will soon be followed by significant European expansion through the opening of a newly scaled, state-of-the-art GMP facility that will co-locate both KBI Biopharma and Selexis SA in Geneva, Switzerland .
About JSR Life Sciences, LLC
A business unit of JSR Corporation, JSR Life Science LLC is changing human health as a strategic partner and pathfinder for the life sciences industry. Rooted in a history of materials innovation, JSR LS provides specialized products, materials, and services to biopharmaceutical companies and academic researchers. Together with its world-class affiliates, JSR LS offers best-in-class integrated services that de-risk molecule selection, accelerate biologic development timelines, increase clinical success rates, and develop novel in vitro diagnostics. JSR LS’s global network of affiliates includes Crown Bioscience, KBI Biopharma, Inc., Selexis SA, and MEDICAL & BIOLOGICAL LABORATORIES CO., LTD. The company operates R&D and applications labs, manufacturing facilities, and sales offices worldwide. For more information, visit JSRLifeSciences.com
About KBI Biopharma
KBI Biopharma, a JSR Life Sciences company, is a global contract development and manufacturing organization (CDMO) providing fully integrated, accelerated drug development and biologics manufacturing services and expertise to life science companies. With each of its 500+ client partners, KBI works closely to personalize and rapidly accelerate drug development programs. Built upon a foundation of world-class analytics capabilities and extensive scientific and technical expertise, KBI delivers robust process development and clinical and commercial cGMP manufacturing services for mammalian, microbial, and cell therapy programs. Recognized for quality manufacturing, KBI helps partners advance drug candidates into the clinic and beyond. KBI serves its global partners with multiple locations in Europe and the USA. www.kbibiopharma.com .
About Selexis SA
Selexis SA, a JSR Life Sciences company, is the global leader in cell line development with best-in-class modular technology and highly specialized solutions that enable the life sciences industry to rapidly discover, develop and commercialize innovative medicines and vaccines. Our global partners are utilizing Selexis technologies to advance more than 155 drug candidates in preclinical and clinical development and the manufacture of nine commercial products. As part of a comprehensive drug development process, the Company’s technologies shorten development timelines and reduce manufacturing risks. More information is available at www.selexis.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220502005028/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Verlinvest to Facilitate China Resources’ Full Exit From Oatly20.11.2026 22:30:00 CET | Press release
Proposed facilitation of China Resources’ exit from Oatly requires a tender offer because of Swedish law requirements Verlinvest recommends that Oatly shareholders and holders of ADSs do not tender their shares or ADSs. Verlinvest, the global, family-backed consumer-focused evergreen investment company, today announced it has entered into an agreement to acquire China Resources Enterprise, Limited’s (“China Resources”) indirect interests in Oatly Group AB (publ) (Nasdaq: OTLY) (“Oatly”), the world’s original and largest oat drink company. The transaction builds on Verlinvest’s investment in Oatly since 2016 and reinforces its conviction in the company’s long-term potential. A change in strategic direction of state-owned enterprise China Resources informed its decision to fully exit its investment in Oatly. China Resources worked constructively with Verlinvest to identify the best path for it to do so in recognition of the complexity of their joint holding structure. Under the agreement
Picsart Opens the AI Behind Its Platform to Developers & Businesses20.11.2026 20:54:00 CET | Press release
With Picsart Platform, developers can build their own video, audio, image features using 250+ models from 30+ providers, alongside Picsart's own editing models, through one API, CLI or MCP server. Key Takeaways One bundle, four ways to build: the API, the CLI, a playground to test models, and Picsart Media Studio, an MCP server that works with compatible AI assistants. One integration for image, video, audio and text generation from 250+ models across 30+ providers, with the freedom to switch models as a product evolves. Self-serve users pay per generation at competitive, published rates. Developers get access to Picsart's proprietary editing models, like Enhance and background removal, which are only available on Picsart Platform. Picsart, the AI media production and distribution platform backed by Sequoia Capital and SoftBank Vision Fund 2, today launched Picsart Platform - a multimodal creative AI hub that gives developers the technology behind the platform used by more than 100 mil
NetJets Becomes Official Private Aviation Provider of the Hahnenkamm Races in Kitzbühel20.11.2026 18:45:00 CET | Press release
The Partnership brings together two brands committed to excellence, precision and exceptional experiences NetJets, the global leader in private aviation, is delighted to announce its newest partnership with the Hahnenkamm Races in Kitzbühel, Austria, becoming the event's Official Private Aviation Provider. The Hahnenkamm Races are among the most prestigious and celebrated events in world alpine skiing. They attract athletes, business leaders, international guests and winter sports enthusiasts from around the world. Through this partnership, NetJets and the Hahnenkamm Races are aligning two brands renowned for excellence, precision and world-class experiences. The partnership is an exciting addition to NetJets' growing portfolio of premium lifestyle and sporting partnerships, offering Owners unique opportunities to access one of Europe's most iconic winter sporting events. Alongside premium hospitality and unforgettable behind-the-scenes experiences, the collaboration will help create e
Frontgrade Technologies Help Power Critical Computing and Electronics Aboard NASA’s Roman Space Telescope20.11.2026 18:40:00 CET | Press release
Frontgrade processors and radiation-hardened microelectronics support critical spacecraft and instrument functions on NASA’s flagship astrophysics mission Frontgrade today announced that technologies from across its space electronics portfolio are supporting multiple mission-critical systems aboard NASA’s Nancy Grace Roman Space Telescope, which successfully launched on August 30, 2026. Roman is NASA’s flagship astrophysics observatory designed to investigate dark energy, discover exoplanets and explore the evolution of the universe. Its onboard electronics include radiation-hardened processors and microelectronics, providing critical processing, communications, power-management and control functions across the spacecraft. At the centre of Roman’s computing architecture are Frontgrade Gaisler’s GR740 and GR712RC processors. The GR740 radiation-hardened quad-core LEON4FT processor serves as the computing engine for the Wildcat Processor Card, used in the spacecraft’s primary and redunda
Inside Moutai House Singapore: Beyond Baijiu, A Cultural Encounter20.11.2026 16:05:00 CET | Press release
On November 13, Moutai House officially opened at Fullerton Waterboat House in Singapore. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261120301288/en/ On November 13, Moutai House officially opened at Fullerton Waterboat House in Singapore. As the world’s first Moutai brand experience space built under its new SI standards, this three-storey venue brings together cultural exhibitions, baijiu tasting, distinctive dining and creative cocktails. Using Moutai as a bridge, it creates new opportunities for Chinese baijiu culture to blend with and draw inspiration from Singapore’s diverse lifestyle and cultural scene. As early as 1954, Guizhou Moutai arrived in Singapore via the Singapore River, marking its first entry into Southeast Asia, right across from Fullerton Waterboat House. 72 years later, Moutai House has found its home along the same riverbank, transforming a historic arrival into a lasting presence and turning a con
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
